Tasly Pharmaceutical Group Co., Ltd
PharmaTianjin, China, China · Est. 1994
Tasly Pharmaceutical Group Co., Ltd is a Chinese pharmaceutical company focused on cardiovascular disease treatment and traditional Chinese medicine-based drug development.
4
Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
5
Indications↗
Distinct diseases across all programs
31
Clinical Trials↗
All sponsored trials (all statuses)
Pipeline
Pipeline Snapshot
By Phase
4 drugs in development
Phase 31
Phase 21
Phase 11
By Therapeutic Area
top 4
Infectious Disease
125%
Gastroenterology
125%
Oncology
125%
Cardiovascular
125%
R&D Momentum
54/100
Pipeline Velocity
27/100
Trial Completion Rate
100/100
Pipeline Concentration
25/100
Pipeline Freshness
84/100
Strategic Signals
- ↗Active in Infectious Disease but thin pipeline — potential licensing opportunity
Activity
Recent Activity
Earlier
Apr 30, 2026TrialA Study of the Effectiveness and Safety of JS1-1-01 Tablet in Patients With Moderate to Severe Depression
Jan 5, 2026TrialA Clinical Trial of P134 Cells in Recurrent Glioblastoma
Jan 1, 2026TrialA Clinical Trial Evaluating the Efficacy and Safety of Sanhuang Jingshiming Pills in the Treatment of nAMD
Dec 31, 2025TrialA Study of the Safety, Tolerability and Preliminary Efficacy of B2065 in Patients With Acute Ischemic Stroke.
Dec 26, 2025TrialA Phase I/II Clinical Trial of Intramyocardial Injection of HucMSCs for the Treatment of Chronic Heart Failure
Sep 1, 2025TrialPhase III Trial of Susu Zhike Granules in Children With Cold-cough Syndrome for Acute Cough Treatment
Feb 27, 2025TrialA Study of Lianxiaxiaopi Granules in the Treatment of Postprandial Distress Syndrome
4 more events
Jan 31, 2025TrialEfficacy and Safety of Jia Shen Tablets in Chronic Heart Failure
Dec 30, 2024TrialEfficacy and Safety of Changkang Granules in the Treatment of Irritable Bowel Syndrome With Predominant Diarrhea (Liver qi Affecting the Spleen Pattern)
Sep 27, 2024TrialA Study of the Safety and Efficacy of Pimavanserin in Patients With Parkinson's Disease Psychosis
Apr 26, 2024TrialEfficacy and Safety of Xiangjurupining Capsule for Hyperplasia of Mammary Glands
Details
Company Info
Therapeutic Focus
Cardiovascular diseaseTraditional Chinese MedicinePharmaceutical manufacturing
Pipeline
Drug Pipeline
Indication
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Cardiovascular
Gastroenterology
Infectious Disease
Cardiovascular
Ischemic Stroke
B2065Phase 2
Gastroenterology
Infectious Disease
Common Cold
Antiwei GranulesPhase 3
Oncology
Endometrial Cancer
STRO-002Phase 1
Ovarian Cancer
STRO-002Phase 1
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)